The European Commission approved Raptor Pharmaceutical's application to market its nephropathic cystinosis drug Procysbi in the European Union. The drugmaker must obtain approval from each country. Raptor CEO Chris Starr said the action "brings us a major step closer to providing access to this important new therapeutic option to cystinosis patients in Europe."

Related Summaries